What is starting to emerge is an impact on the routine evaluation of patients, on treatment choices, and on the enrollment and adherence to clinical trials. Optimal management of patients with CLL requires extensive laboratory support in terms of di- agnostic testing, genetic-based prognostic stratification, and monitoring of minimal residual disease. The survey has high- lighted that these steps could not always be optimally guar- anteed during the pandemic, which has started to affect the number of new cases, the adequate follow-up of treated pa- tients, the number of patients enrolled in clinical trials.
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report
Quaglia, Francesca Maria;
2020-01-01
Abstract
What is starting to emerge is an impact on the routine evaluation of patients, on treatment choices, and on the enrollment and adherence to clinical trials. Optimal management of patients with CLL requires extensive laboratory support in terms of di- agnostic testing, genetic-based prognostic stratification, and monitoring of minimal residual disease. The survey has high- lighted that these steps could not always be optimally guar- anteed during the pandemic, which has started to affect the number of new cases, the adequate follow-up of treated pa- tients, the number of patients enrolled in clinical trials.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
